Skip To Main Content { "isEditMode": false, "isPublic": true, "context": "", "site": "campus-sanofi-mx", "currentLocale": "es_MX", "translationsPath": "" } [{ event: `metadata`,device: /(tablet|ipad|playbook|silk)|(android(?!.*mobi))/i.test(navigator.userAgent) ? 'tablet' : (/Mobile|iP(hone|od)|Android|BlackBerry|IEMobile|Kindle|Silk-Accelerated|(hpw|web)OS|Opera M(obi|ini)/.test(navigator.userAgent) ? 'mobile' : 'desktop'),platform: `magnolia`,language: `es`,siteType: `advise`,brandWebsiteType: `multibrand`,target: `hcp`,gbu: `GBU - Specialty care`,franchise: `RARE BLOOD DISORDERS`,therapeutic_area: `RARE BLOOD DISORDERS`,pageName: `Estudio IKEMA: mieloma`,page_type: `content article page` }] Este sitio es exclusivo para profesionales de la salud en México.
-
-
-
{ event: "article_read", name: `Estudio IKEMA: mieloma`, author: ``, tags: `Otras Medicinas Generales`, publication_date: `2023-05-04`, interaction_type: "content" } - Article
- Source: Campus Sanofi
-
Estudio IKEMA: mieloma
Estudio IKEMA: Myeloma Insights del Dr. Karthik Ramasamy
